

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version 2.1 Revision Date: 30.09.2023 SDS Number: 3177574-00013 Date of last issue: 04.04.2023
Date of first issue: 18.09.2018

SECTION 1. IDENTIFICATION

Product name : Ezetimibe / Rosuvastatin Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 1-551-430-6000

Emergency telephone : 1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Skin corrosion/irritation : Category 3

Carcinogenicity : Category 1B

Reproductive toxicity : Category 1B

Specific target organ toxicity - single exposure (Oral) : Category 2 (Liver, Kidney, muscle)

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Eye)

Long-term (chronic) aquatic hazard : Category 2

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H316 Causes mild skin irritation.
H350 May cause cancer.

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version 2.1 Revision Date: 30.09.2023 SDS Number: 3177574-00013 Date of last issue: 04.04.2023
Date of first issue: 18.09.2018

H360FD May damage fertility. May damage the unborn child.
H371 May cause damage to organs (Liver, Kidney, muscle) if swallowed.
H373 May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.
H411 Toxic to aquatic life with long lasting effects.

Precautionary Statements

:

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P332 + P313 If skin irritation occurs: Get medical advice/ attention.
P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 -< 20
Ezetimibe	163222-33-1	>= 5 -< 10
Rosuvastatin	147098-20-2	>= 2,5 -< 5
Sodium n-dodecyl sulfate	151-21-3	>= 1 -< 2,5
Magnesium stearate	557-04-0	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : Causes mild skin irritation.
May cause cancer.
May damage fertility. May damage the unborn child.
May cause damage to organs if swallowed.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Fluorine compounds
Nitrogen oxides (NO_x)
Sulfur oxides
Metal oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Ezetimibe / Rosuvastatin Formulation

Version 2.1 Revision Date: 30.09.2023 SDS Number: 3177574-00013 Date of last issue: 04.04.2023
Date of first issue: 18.09.2018

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	CMP	10 mg/m ³	AR OEL
		TWA	10 mg/m ³	ACGIH
Ezetimibe	163222-33-1	TWA	25 µg/m ³ (OEB 3)	Internal
		Wipe limit	250 µg/100 cm ²	Internal
Rosuvastatin	147098-20-2	TWA	20 µg/m ³ (OEB 3)	Internal
		Wipe limit	200 µg/100 cm ²	Internal
Magnesium stearate	557-04-0	CMP	10 mg/m ³	AR OEL
Further information: A4 - Not classifiable as a human carcinogen				
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

Skin and body protection	:	Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	white to off-white
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version 2.1 Revision Date: 30.09.2023 SDS Number: 3177574-00013 Date of last issue: 04.04.2023
Date of first issue: 18.09.2018

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5.000 mg/kg
Method: Calculation method

Ezetimibe / Rosuvastatin Formulation

Version 2.1 Revision Date: 30.09.2023 SDS Number: 3177574-00013 Date of last issue: 04.04.2023
Date of first issue: 18.09.2018

Components:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Ezetimibe:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg
LD50 (Mouse): > 5.000 mg/kg
LD50 (Dog): > 3.000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 2.000 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): > 1.000 - < 2.000 mg/kg
Application Route: Intraperitoneal

Rosuvastatin:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Target Organs: Liver, Stomach, muscle, Kidney

Sodium n-dodecyl sulfate:

Acute oral toxicity : LD50 (Rat): 1.200 mg/kg
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Remarks: Based on data from similar materials

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

Skin corrosion/irritation

Causes mild skin irritation.

Components:**Ezetimibe:**

Species	:	Rabbit
Result	:	No skin irritation

Sodium n-dodecyl sulfate:

Species	:	Rabbit
Result	:	Skin irritation

Magnesium stearate:

Species	:	Rabbit
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Ezetimibe:**

Species	:	Rabbit
Result	:	No eye irritation

Sodium n-dodecyl sulfate:

Species	:	Rabbit
Result	:	Irreversible effects on the eye
Method	:	OECD Test Guideline 405

Magnesium stearate:

Species	:	Rabbit
Result	:	No eye irritation
Remarks	:	Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Ezetimibe:**

Test Type	:	Maximization Test
Species	:	Guinea pig
Result	:	negative

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

Sodium n-dodecyl sulfate:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Result	:	negative
Remarks	:	Based on data from similar materials

Magnesium stearate:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

Ezetimibe:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Metabolic activation: with and without metabolic activation Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative

Rosuvastatin:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Test system: Escherichia coli Result: negative
-----------------------	---	---

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

Test Type: Chromosomal aberration
 Test system: Chinese hamster lung cells
 Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
 Species: Mouse
 Cell type: Bone marrow
 Application Route: Ingestion
 Result: negative

Sodium n-dodecyl sulfate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Method: OECD Test Guideline 471
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
 Method: OECD Test Guideline 473
 Result: negative
 Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative
 Remarks: Based on data from similar materials

Carcinogenicity

May cause cancer.

Components:**Cellulose:**

Species : Rat
 Application Route : Ingestion
 Exposure time : 72 weeks
 Result : negative

Ezetimibe:

Species : Rat, female
 Application Route : oral (feed)

Ezetimibe / Rosuvastatin Formulation

Version 2.1 Revision Date: 30.09.2023 SDS Number: 3177574-00013 Date of last issue: 04.04.2023
Date of first issue: 18.09.2018

Exposure time : 104 weeks
Result : negative

Species : Rat, male
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Species : Mouse
Application Route : oral (feed)
Exposure time : 104 weeks
Result : negative

Rosuvastatin:

Species : Rat
Application Route : Oral
Exposure time : 104 weeks
LOAEL : 80 mg/kg body weight
Result : positive
Symptoms : Tumor
Target Organs : Uterus (including cervix)

Species : Mouse
Application Route : Oral
Exposure time : 107 weeks
LOAEL : 200 mg/kg body weight
Result : positive
Symptoms : liver adenoma, carcinoma
Target Organs : Liver

Sodium n-dodecyl sulfate:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Method : OECD Test Guideline 453
Result : negative
Remarks : Based on data from similar materials

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

Ezetimibe:

- Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Fertility: NOAEL: > 1.000 mg/kg body weight
Result: No effects on fertility., No fetotoxicity.
- Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight
Result: No adverse effects.
- Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: > 1.000 mg/kg body weight
Result: No adverse effects.

Rosuvastatin:

- Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 50 mg/kg body weight
- Test Type: Fertility
Species: Monkey
Application Route: Oral
Fertility: LOAEL: 30 mg/kg body weight
Result: Effects on male and female reproductive organs.
- Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 50 mg/kg body weight
Result: Fetal mortality.
- Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 3 mg/kg body weight
Result: Fetal mortality., Maternal toxicity observed.

Reproductive toxicity - Assessment : May damage fertility. May damage the unborn child.

Sodium n-dodecyl sulfate:

- Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: Based on data from similar materials

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

May cause damage to organs (Liver, Kidney, muscle) if swallowed.

Components:

Rosuvastatin:

Routes of exposure : Oral
Target Organs : Liver, Kidney, muscle
Assessment : Causes damage to organs.

STOT-repeated exposure

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

Components:

Rosuvastatin:

Routes of exposure : Oral
Target Organs : Eye
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat
NOAEL : ≥ 9.000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Ezetimibe:

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version 2.1 Revision Date: 30.09.2023 SDS Number: 3177574-00013 Date of last issue: 04.04.2023
Date of first issue: 18.09.2018

Species : Dog
NOAEL : 1.000 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 1.500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 300 mg/kg
Application Route : Oral
Exposure time : 1 y
Remarks : No significant adverse effects were reported

Rosuvastatin:

Species : Dog
LOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 24 Days
Target Organs : Brain
Symptoms : Edema, Blood disorders, Necrosis
Remarks : Based on data from similar materials

Species : Dog
LOAEL : 6 mg/kg
Application Route : Oral
Exposure time : 52 Weeks
Target Organs : Cornea
Symptoms : Corneal opacity
Remarks : Based on data from similar materials

Species : Dog
LOAEL : 30 mg/kg
Application Route : Oral
Exposure time : 12 Weeks
Target Organs : Eye
Symptoms : Eye disease
Remarks : Based on data from similar materials

Species : Dog
LOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : eye - retina

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version 2.1 Revision Date: 30.09.2023 SDS Number: 3177574-00013 Date of last issue: 04.04.2023
Date of first issue: 18.09.2018

Symptoms : Eye disease
Remarks : Based on data from similar materials

Sodium n-dodecyl sulfate:

Species : Rat
NOAEL : 488 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:

Ezetimibe:

Not applicable

Experience with human exposure

Components:

Ezetimibe:

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

Rosuvastatin:

Ingestion : Target Organs: Kidney
Symptoms: kidney toxicity
Remarks: Based on Human Evidence
Target Organs: muscle
Symptoms: musculoskeletal pain
Remarks: Based on Human Evidence
Target Organs: Liver
Symptoms: liver function change
Remarks: Based on Human Evidence

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

Exposure time: 48 h
Remarks: Based on data from similar materials

Ezetimibe:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0,125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0,317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0,317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0,051 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,282 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility.

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 4,4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

NOEC: 4,4 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.

Rosuvastatin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1.000 mg/l

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

Exposure time: 96 hrs
Method: FDA 4.11

LC50 (Lepomis macrochirus (Bluegill sunfish)): > 1.000 mg/l
Exposure time: 96 hrs
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 63 mg/l
Exposure time: 48 hrs
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Microcystis aeruginosa (blue-green algae)): > 640 mg/l
Exposure time: 96 hrs
Method: FDA 4.01

NOEC (Microcystis aeruginosa (blue-green algae)): 330 mg/l
Exposure time: 96 hrs
Method: FDA 4.01

EC50 (Pseudokirchneriella subcapitata (green algae)): > 800 mg/l
Exposure time: 96 hrs
Method: FDA 4.01

NOEC (Pseudokirchneriella subcapitata (green algae)): 350 mg/l
Exposure time: 96 hrs
Method: FDA 4.01

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 Days
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0,018 mg/l
Exposure time: 21 Days
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50: > 100 mg/l
Exposure time: 3 hrs
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 100 mg/l
Exposure time: 3 hrs
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Sodium n-dodecyl sulfate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 29 mg/l
Exposure time: 96 h

Toxicity to daphnia and other : EC50 (Ceriodaphnia dubia (water flea)): 5,55 mg/l

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

aquatic invertebrates	Exposure time: 48 h
Toxicity to algae/aquatic plants	: ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l Exposure time: 72 h NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l Exposure time: 72 h
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): >= 1,357 mg/l Exposure time: 42 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Ceriodaphnia dubia (water flea)): 0,88 mg/l Exposure time: 7 d
Toxicity to microorganisms	: EC50: 135 mg/l Exposure time: 3 h

Magnesium stearate:

Toxicity to fish	: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	: EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility. NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	: EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Ezetimibe / Rosuvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023
2.1 30.09.2023 3177574-00013 Date of first issue: 18.09.2018

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Ezetimibe:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 6,8 %
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4,5 d)
Method: OECD Test Guideline 111

Rosuvastatin:

Biodegradability : Biodegradation: < 10 %
Exposure time: 28 Days
Method: OECD Test Guideline 301F
Remarks: Not inherently biodegradable.

Stability in water : Hydrolysis: < 10 %(5 Days)

Sodium n-dodecyl sulfate:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 95 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential**Components:****Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 173
Exposure time: 97 d
Method: OECD Test Guideline 305

Partition coefficient: n-
octanol/water : log Pow: 4,36

Rosuvastatin:

Partition coefficient: n-
octanol/water : log Pow: 0,3

Sodium n-dodecyl sulfate:

Partition coefficient: n- : log Pow: 0,83

Ezetimibe / Rosuvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

octanol/water

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil**Components:****Ezetimibe:**

Distribution among environmental compartments : log Koc: 4,35
Method: OECD Test Guideline 106

Rosuvastatin:

Distribution among environmental compartments : log Koc: 2,15
Method: FDA 3.08

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Ezetimibe, Rosuvastatin)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Ezetimibe, Rosuvastatin)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 956

Packing instruction (passenger aircraft) : 956

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

ger aircraft)
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,
N.O.S.
(Ezetimibe, Rosuvastatin)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 30.09.2023
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Full text of other abbreviations

SAFETY DATA SHEET



Ezetimibe / Rosuvastatin Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
2.1	30.09.2023	3177574-00013	Date of first issue: 18.09.2018

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
AR OEL	:	Argentina. Occupational Exposure Limits
ACGIH / TWA	:	8-hour, time-weighted average
AR OEL / CMP	:	TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8